Answers are grounded in this paper and cite their sources.
In connection with a program directed at potent and balanced dual NK1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pK i values of 8.6 and 8.1, respectively.
No takes yet. Share an insight, caveat, or question.
Hanessian et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: